OncoMatch/Clinical Trials/NCT05892718
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Is NCT05892718 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies HCB101 for advanced solid tumor.
Treatment: HCB101 — The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic cancer therapy
advanced solid tumors refractory to standard therapy, or for which no standard treatment exists or non-Hodgkin lymphoma, relapsed or refractory to at least 2 prior lines of therapy
Cannot have received: CD47 or SIRPA pathway inhibitor
Have received any treatment targeting the CD47 or SIRPα pathway
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hematology-Oncology Associates of the Treasure Coast · Port Saint Lucie, Florida
- Carolina BioOncology · Huntersville, North Carolina
- Greenville Hospital System University Medical Center (ITOR) · Greenville, South Carolina
- UT Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05892718 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD47 or SIRPA pathway inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages